Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Mimetics: the future of AML treatment?

Andrew Wei • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Venetoclax

When considering what treatment to prescribe for acute myeloid leukemia (AML), an advanced age is a limiting factor. With recent developments in treatment perhaps this will no longer be the case. In this interview, Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of BH3 mimetics, such as venetoclax, and immunotherapy drugs for the treatment of elderly patients with AML. Dr Wei also discusses the future applications of mimetics in AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrew Wei

New approaches to target TP53-mutated AML: the ADAPT trial
10:05
New approaches to target TP53-mutated AML: the ADAPT trial
Andrew Wei • 20 Sep 2026
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
18:47
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
Andrew Wei et al. • 20 Sep 2026
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
Andrew Wei et al. • 19 Sep 2025
Current challenges in clinical genomics
Current challenges in clinical genomics
Andrew Wei et al. • 29 Sep 2022

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals